Annual EBITDA
-$103.70 M
+$57.55 M+35.69%
December 31, 2023
Summary
- As of February 26, 2025, RLMD annual EBITDA is -$103.70 million, with the most recent change of +$57.55 million (+35.69%) on December 31, 2023.
- During the last 3 years, RLMD annual EBITDA has fallen by -$42.87 million (-70.47%).
- RLMD annual EBITDA is now -886244.44% below its all-time high of -$11.70 thousand, reached on August 31, 2012.
Performance
RLMD EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$23.01 M
-$4.19 M-22.26%
September 30, 2024
Summary
- As of February 26, 2025, RLMD quarterly EBITDA is -$23.01 million, with the most recent change of -$4.19 million (-22.26%) on September 30, 2024.
- Over the past year, RLMD quarterly EBITDA has dropped by -$20.90 thousand (-0.09%).
- RLMD quarterly EBITDA is now -521.68% below its all-time high of $5.46 million, reached on December 31, 2014.
Performance
RLMD Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$91.64 M
-$316.20 K-0.35%
September 30, 2024
Summary
- As of February 26, 2025, RLMD TTM EBITDA is -$91.64 million, with the most recent change of -$316.20 thousand (-0.35%) on September 30, 2024.
- Over the past year, RLMD TTM EBITDA has increased by +$6.89 million (+6.99%).
- RLMD TTM EBITDA is now -8085.78% below its all-time high of $1.15 million, reached on September 30, 2015.
Performance
RLMD TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
RLMD EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +35.7% | -0.1% | +7.0% |
| 3 y3 years | -70.5% | +46.1% | +18.5% |
| 5 y5 years | -715.1% | -520.8% | -799.2% |
RLMD EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +35.7% | -22.3% | +49.4% | -0.3% | +43.2% |
| 5 y | 5-year | -1154.0% | +35.7% | -520.8% | +49.4% | -799.2% | +43.2% |
| alltime | all time | <-9999.0% | +35.7% | -521.7% | +49.4% | -8085.8% | +43.2% |
Relmada Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$23.01 M(+22.3%) | -$91.64 M(+0.3%) |
| Jun 2024 | - | -$18.82 M(-18.1%) | -$91.33 M(-7.3%) |
| Mar 2024 | - | -$22.99 M(-14.3%) | -$98.54 M(-5.0%) |
| Dec 2023 | -$103.70 M(-35.7%) | -$26.83 M(+18.2%) | -$103.70 M(-10.3%) |
| Sep 2023 | - | -$22.69 M(-12.8%) | -$115.58 M(-12.2%) |
| Jun 2023 | - | -$26.03 M(-7.6%) | -$131.62 M(-12.9%) |
| Mar 2023 | - | -$28.15 M(-27.3%) | -$151.11 M(-6.3%) |
| Dec 2022 | -$161.25 M(+28.3%) | -$38.70 M(-0.1%) | -$161.25 M(+2.9%) |
| Sep 2022 | - | -$38.74 M(-14.9%) | -$156.73 M(-2.4%) |
| Jun 2022 | - | -$45.51 M(+18.8%) | -$160.65 M(+13.5%) |
| Mar 2022 | - | -$38.30 M(+12.0%) | -$141.60 M(+12.6%) |
| Dec 2021 | -$125.70 M(+106.6%) | -$34.18 M(-19.9%) | -$125.70 M(+11.8%) |
| Sep 2021 | - | -$42.65 M(+61.2%) | -$112.44 M(+29.3%) |
| Jun 2021 | - | -$26.46 M(+18.1%) | -$86.97 M(+18.7%) |
| Mar 2021 | - | -$22.40 M(+7.1%) | -$73.27 M(+20.4%) |
| Dec 2020 | -$60.83 M(+635.7%) | -$20.92 M(+21.8%) | -$60.83 M(+52.4%) |
| Sep 2020 | - | -$17.18 M(+34.7%) | -$39.91 M(+51.0%) |
| Jun 2020 | - | -$12.76 M(+27.9%) | -$26.44 M(+89.0%) |
| Mar 2020 | - | -$9.97 M(+169.1%) | -$13.99 M(+37.2%) |
| Dec 2019 | -$8.27 M(-35.0%) | - | - |
| Sep 2019 | - | -$3.71 M(+1113.2%) | -$10.19 M(+14.6%) |
| Jun 2019 | -$12.72 M(+84.0%) | -$305.50 K(-88.7%) | -$8.90 M(-16.1%) |
| Mar 2019 | - | -$2.70 M(-22.4%) | -$10.60 M(-1.0%) |
| Dec 2018 | - | -$3.48 M(+44.4%) | -$10.71 M(+23.3%) |
| Sep 2018 | - | -$2.41 M(+19.8%) | -$8.68 M(+19.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2018 | -$6.91 M(-3.1%) | -$2.01 M(-28.2%) | -$7.25 M(+3.5%) |
| Mar 2018 | - | -$2.80 M(+92.6%) | -$7.01 M(+8.4%) |
| Dec 2017 | - | -$1.46 M(+48.5%) | -$6.46 M(-0.9%) |
| Sep 2017 | - | -$980.30 K(-44.4%) | -$6.52 M(-8.6%) |
| Jun 2017 | -$7.13 M(-55.9%) | -$1.76 M(-21.9%) | -$7.13 M(-15.6%) |
| Mar 2017 | - | -$2.26 M(+49.4%) | -$8.45 M(-5.2%) |
| Dec 2016 | - | -$1.51 M(-5.2%) | -$8.91 M(-32.1%) |
| Sep 2016 | - | -$1.60 M(-48.2%) | -$13.12 M(+91.4%) |
| Jun 2016 | -$16.16 M(-5.4%) | -$3.08 M(+13.3%) | -$6.85 M(-16.1%) |
| Mar 2016 | - | -$2.72 M(-52.5%) | -$8.17 M(-18.5%) |
| Dec 2015 | - | -$5.72 M(-222.6%) | -$10.03 M(-973.8%) |
| Sep 2015 | - | $4.67 M(-206.1%) | $1.15 M(-103.4%) |
| Jun 2015 | -$17.09 M(-18.2%) | -$4.40 M(-3.9%) | -$33.35 M(+15.2%) |
| Mar 2015 | - | -$4.58 M(-183.9%) | -$28.95 M(+18.8%) |
| Dec 2014 | - | $5.46 M(-118.3%) | -$24.38 M(-18.3%) |
| Sep 2014 | - | -$29.83 M(>+9900.0%) | -$29.85 M(>+9900.0%) |
| Jun 2014 | -$20.90 M(>+9900.0%) | - | - |
| Feb 2014 | - | -$3000.00(-78.9%) | -$48.80 K(-2.2%) |
| Nov 2013 | - | -$14.20 K(+16.4%) | -$49.90 K(+11.6%) |
| Aug 2013 | -$44.80 K(+282.9%) | -$12.20 K(-37.1%) | -$44.70 K(+8.8%) |
| May 2013 | - | -$19.40 K(+373.2%) | -$41.10 K(+69.8%) |
| Feb 2013 | - | -$4100.00(-54.4%) | -$24.20 K(+19.8%) |
| Nov 2012 | - | -$9000.00(+4.7%) | -$20.20 K(+80.4%) |
| Aug 2012 | -$11.70 K | -$8600.00(+244.0%) | -$11.20 K(+330.8%) |
| May 2012 | - | -$2500.00(+2400.0%) | -$2600.00(+2500.0%) |
| Feb 2012 | - | -$100.00 | -$100.00 |
FAQ
- What is Relmada Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Relmada Therapeutics?
- What is Relmada Therapeutics annual EBITDA year-on-year change?
- What is Relmada Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Relmada Therapeutics?
- What is Relmada Therapeutics quarterly EBITDA year-on-year change?
- What is Relmada Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Relmada Therapeutics?
- What is Relmada Therapeutics TTM EBITDA year-on-year change?
What is Relmada Therapeutics annual EBITDA?
The current annual EBITDA of RLMD is -$103.70 M
What is the all time high annual EBITDA for Relmada Therapeutics?
Relmada Therapeutics all-time high annual EBITDA is -$11.70 K
What is Relmada Therapeutics annual EBITDA year-on-year change?
Over the past year, RLMD annual EBITDA has changed by +$57.55 M (+35.69%)
What is Relmada Therapeutics quarterly EBITDA?
The current quarterly EBITDA of RLMD is -$23.01 M
What is the all time high quarterly EBITDA for Relmada Therapeutics?
Relmada Therapeutics all-time high quarterly EBITDA is $5.46 M
What is Relmada Therapeutics quarterly EBITDA year-on-year change?
Over the past year, RLMD quarterly EBITDA has changed by -$20.90 K (-0.09%)
What is Relmada Therapeutics TTM EBITDA?
The current TTM EBITDA of RLMD is -$91.64 M
What is the all time high TTM EBITDA for Relmada Therapeutics?
Relmada Therapeutics all-time high TTM EBITDA is $1.15 M
What is Relmada Therapeutics TTM EBITDA year-on-year change?
Over the past year, RLMD TTM EBITDA has changed by +$6.89 M (+6.99%)